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Editorial Note: The gender ini-
tiative, a provocative series ad-
dressing gender differences in
the surgical treatment of car-
diac, vascular, and thoracic dis-
ease, continues with editorials
addressing long-term outcomes
of coronary artery surgery in
women. Suzanne Oparil, MD, a
cardiologist renowned for clini-
cal and laboratory studies of
women with cardiovascular dis-
ease, provides an excellent
overview. Viola Vaccarino, MD,
PhD, and Colleen Koch, MD, ad-
dress specific issues involving
cardiac rehabilitation, quality of
life, relief of symptoms, and
long-term survival after cardiac
surgery. The series continues
next month with editorials ad-
dressing valvular heart disease
in women.
Nancy A. Nussmeier, MD
Texas Heart Institute
See related articles on pages
1707, 2032, and 2044.
In this issue of the Journal,Vaccarino and Koch1 and Koch and associates2,3come to grips with the knotty and contentious problem of why women havepoorer outcomes than men after coronary artery bypass grafting (CABG).They use a database of 15,597 patients, including 3596 women, whounderwent isolated CABG surgery at a single institution between 1993 and2002 to address the question: “Is female gender a marker or a cause of
increased risk of poor outcomes after coronary revascularization?” They observe an
increased burden of cardiovascular disease risk factors and comorbid conditions,
including hypertension, insulin-treated diabetes, heart failure, renal disease, periph-
eral vascular disease, and elevated low-density lipoprotein cholesterol and triglyc-
eride levels, in women compared with men. Further, women had a more unstable
presentation, including a higher prevalence of unstable angina, preoperative intra-
aortic balloon pump usage, and emergency surgery, compared with men. When
propensity modeling techniques were used, only 26% of women could be matched
on propensity scores with men because of the greater prevalence of risk factors and
comorbidities among the women. While unadjusted postoperative morbidity and
mortality outcomes were worse for women than for men overall, in well-matched
patients, female gender was not a risk factor for in-hospital mortality and had
minimal impact on postoperative morbidity.
The authors go on to discuss gender disparities in the long-term outcomes of
CABG surgery, which include less relief of angina, more dyspnea, and lower
functional status in women, without a reduction in survival. They point out an
encouraging trend toward improved CABG outcomes in women, which they relate
to technical advancements in surgical and myocardial protection techniques. The
cardiovascular surgeons and their colleagues in anesthesiology deserve kudos for
the major advances that they have made in this area. To achieve further gains in
CABG outcomes for women, however, it is apparent that more needs to be done to
facilitate the earlier diagnosis of clinically important coronary artery disease and
related comorbid conditions in women. This approach should improve their cardio-
vascular risk profiles at the time of presentation for surgery, as well as their
perioperative and postoperative outcomes. Even more important, aggressive strat-
egies of lifestyle modification and cardiovascular risk factor reduction are urgently
needed to reduce both the risk of CABG surgery and the need for the procedure in
older women.
Effective methods for reducing cardiovascular risk by both lifestyle modification
and pharmacologic means are clearly available, but there is evidence that these are
underused in the very women who are at highest risk for cardiovascular disease and
therefore become candidates for CABG surgery.4 For example, hypertension, the
most common modifiable cardiovascular risk factor in women, is clearly inade-
quately managed in older women. The majority of women over age 65 years in the
United States are hypertensive, and the prevalence of hypertension tracks closely
with the prevalence of cardiovascular disease.5 Abundant clinical trial evidence
indicates that antihypertensive therapy is highly effective in preventing target organ
damage, including heart attack, heart failure, and stroke, in women, as well as in
men.6,7 Nevertheless, as shown in data from the Women’s Health Initiative (WHI),
hypertension is undertreated and inadequately controlled in women, particularly in
high-risk elderly women.8 In the WHI cohort, blood pressure control rates were
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inversely related to age, declining from 41% in women in
their 50s to 29% in those older than 70 years, despite similar
rates of antihypertensive drug treatment in the three de-
cades. The majority of treated hypertensive women received
only a single drug, an approach that has been repeatedly
shown to be ineffective in controlling blood pressure, par-
ticularly in older, high-risk patients.9 WHI data are further
revealing that hypertensive women had a constellation of
risk factors, including overweight and sedentary lifestyle,
that are susceptible to prevention and treatment by lifestyle
modification.
Thresholds for instituting antihypertensive treatment,
blood pressure goals, and choices of antihypertensive drugs
are generally the same for women as for men.9 Lifestyle
modification is clearly indicated in women with clinical
hypertension or with blood pressure in the “prehyperten-
sive” range because of its potential for preventing the pro-
gression to higher blood pressures and cardiovascular dis-
ease outcomes and for increasing the efficacy of
pharmacologic treatment. Of the lifestyle interventions,
weight loss and aerobic exercise are the most efficacious in
reducing blood pressure and related cardiovascular disease
risks such as dyslipidemia.
Similar to blood pressure, lipid levels are strong predic-
tors of risk for coronary heart disease in women, who have
an age-dependent unfavorable trend in lipid levels. Further,
high-risk women derive similar or greater benefit than men
from treatment with 3-hydroxy-3-methylglutaryl coenzyme
A reductase inhibitors (statins).10-12 Accordingly, it is im-
portant to assess lipid levels and global cardiovascular risk
and consider instituting both lifestyle modification and
pharmacologic therapy for dyslipidemia in all women at
menopause. A combination of prudent diet and exercise can
improve levels of triglycerides and high- and low-density
lipoprotein cholesterol.13 Detailed guidelines for thresholds
and goals for pharmacologic treatment are published in the
Third Report of the Expert Panel on Detection, Evaluation
and Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III or ATP III).14 Although treatment rec-
ommendations are generally similar for women and men,
some gender-specific issues play a role in the evaluation and
management of dyslipidemia in women. For example, tri-
glyceride levels are more powerful predictors of coronary
heart disease risk in women than men and require particu-
larly aggressive treatment.
Type 2 diabetes mellitus is a particularly powerful car-
diovascular risk factor in women, equivalent to a history of
myocardial infarction in predicting future coronary events.
The Nurses’ Health Study identified a 3-fold to 7-fold
increase in cardiovascular events in women with type 2
diabetes compared with nondiabetic women .15 The pres-
ence of diabetes is also associated with less favorable out-
comes of percutaneous coronary revascularization,16 and
CABG is the preferred therapy in diabetic patients when
invasive management is required. Accordingly, optimal di-
abetes management is a particularly critical component of
efforts to improve outcomes in women undergoing CABG
surgery. Women with diabetes should be managed with
aggressive risk factor modification emphasizing weight con-
trol and physical activity, as well as use of pharmacologic
therapy to achieve glucose control (goal hemoglobin A1C
 7%), reduction of blood pressure to less than 130/80 mm
Hg, and reduction of low-density lipoprotein cholesterol to
less than 100 mg/dL and non–high-density lipoprotein cho-
lesterol to less than 130 mg/dL.
Clearly, the incisive analysis of Koch and colleagues
reveals that the poorer outcomes observed for women un-
dergoing CABG surgery are not inevitable results of female
gender. Rather, they result from a burden of comorbid
conditions and modifiable risk factors that could be relieved
by greater attention to lifestyle modification and more ag-
gressive management of critical comorbid conditions, par-
ticularly diabetes, earlier in life. The hope for the future is
that improved lifestyles and more diligent medical man-
agement may even the propensity scores and obliterate
the gender disadvantage of older women undergoing
CABG.
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